What is LOME Vomiting?
LOME vomiting refers to Low-Or-Minimal-Emetic-risk vomiting, a classification system used in oncology to categorize the likelihood of nausea and vomiting associated with radiation therapy or chemotherapy treatments.
Classification Framework
The term "LOME" is derived from the emetic risk stratification system used in cancer treatment guidelines:
- Low-emetic-risk: Radiation to the brain, head and neck, thorax, or pelvis 1
- Minimal-emetic-risk: Radiation to extremities or breast; also applies to checkpoint inhibitors (CPIs) when given alone 2, 1
Clinical Significance
This classification system is critical because it determines the prophylactic antiemetic regimen:
For Low-Emetic-Risk Radiation 1:
- Brain radiation: Rescue dexamethasone 4 mg oral or IV (if not already on corticosteroids)
- Head/neck, thorax, pelvis: Offer rescue therapy with:
- 5-HT3 antagonists (ondansetron 8 mg or granisetron 2 mg/1 mg)
- Dexamethasone 4 mg
- Dopamine antagonists (prochlorperazine 5-10 mg or metoclopramide 5-20 mg)
For Minimal-Emetic-Risk 2, 1:
- No routine prophylactic antiemetics required for CPIs administered alone or in combination with another CPI
- Breakthrough therapy available as needed with same agents as low-risk category
Key Distinction from Higher Risk Categories
Unlike high-emetic-risk (total body irradiation) or moderate-emetic-risk (upper abdomen, craniospinal) radiation that require scheduled prophylactic antiemetics before each fraction 1, LOME categories typically use rescue/breakthrough therapy rather than routine prophylaxis 2.
Common Pitfall
Do not confuse LOME with cyclic vomiting syndrome or other vomiting disorders—this is strictly an oncology treatment classification system for predicting and managing treatment-induced nausea and vomiting, not a description of a vomiting pattern or syndrome 2, 1.